Literature DB >> 18832736

B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis.

Raymond S Douglas1, Vibharavi Naik, Catherine J Hwang, Nikoo F Afifiyan, Andrew G Gianoukakis, Daniel Sand, Shweta Kamat, Terry J Smith.   

Abstract

Graves' disease (GD) is an autoimmune process involving the thyroid and connective tissues in the orbit and pretibial skin. Activating anti-thyrotropin receptor Abs are responsible for hyperthyroidism in GD. However, neither these autoAbs nor the receptor they are directed against have been convincingly implicated in the connective tissue manifestations. Insulin-like growth factor-1 receptor (IGF-1R)-bearing fibroblasts overpopulate connective tissues in GD and when ligated with IgGs from these patients, express the T cell chemoattractants, IL-16, and RANTES. Disproportionately large fractions of peripheral blood T cells also express IGF-1R in patients with GD and may account, at least in part, for expansion of IGF-1R(+) memory T cells. We now report a similarly skewed B cell population exhibiting the IGF-1R(+) phenotype from the blood, orbit, and bone marrow of patients with GD. This expression profile exhibits durability in culture and is maintained or increased with CpG activation. Moreover, IGF-1R(+) B cells produce pathogenic Abs against the thyrotropin receptor. In lymphocytes from patients with GD, IGF-1 enhanced IgG production (p < 0.05) and increased B cell expansion (p < 0.02) in vitro while those from control donors failed to respond. These findings suggest a potentially important role for IGF-1R display by B lymphocytes in patients with GD in supporting their expansion and abnormal Ig production.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832736      PMCID: PMC2562248          DOI: 10.4049/jimmunol.181.8.5768

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

1.  Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor.

Authors:  M Navarro; R Baserga
Journal:  Endocrinology       Date:  2001-03       Impact factor: 4.736

Review 2.  Costimulatory molecules and autoimmune thyroid diseases.

Authors:  Claudia Salmaso; Daniel Olive; Giampaola Pesce; Marcello Bagnasco
Journal:  Autoimmunity       Date:  2002-05       Impact factor: 2.815

Review 3.  The insulin-like growth factor system in hematopoietic cells.

Authors:  Walter Zumkeller
Journal:  Leuk Lymphoma       Date:  2002-03

Review 4.  Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy.

Authors:  Lorena Martinez-Gamboa; Hans-Peter Brezinschek; Gerd R Burmester; Thomas Dörner
Journal:  Autoimmun Rev       Date:  2006-03-09       Impact factor: 9.754

5.  Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts.

Authors:  Jane Pritchard; Noah Horst; William Cruikshank; Terry J Smith
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

6.  IGF-1 potentiation of IL-4-induced CD23/Fc(epsilon)RII expression in human B cells.

Authors:  Jeong-Ho Kim; Hyun-Hee Park; Choong-Eun Lee
Journal:  Mol Cells       Date:  2003-06-30       Impact factor: 5.034

7.  The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim.

Authors:  Chun-Rong Chen; Pavel Pichurin; Yuji Nagayama; Francesco Latrofa; Basil Rapoport; Sandra M McLachlan
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

8.  Insulin-like growth factor-I enhances lymphoid and myeloid reconstitution after allogeneic bone marrow transplantation.

Authors:  Onder Alpdogan; Stephanie J Muriglan; Barry J Kappel; Ekaterina Doubrovina; Cornelius Schmaltz; Raffaella Schiro; Jeffrey M Eng; Andrew S Greenberg; Lucy M Willis; Jimmy A Rotolo; Richard J O'Reilly; Marcel R M van den Brink
Journal:  Transplantation       Date:  2003-06-27       Impact factor: 4.939

9.  Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway.

Authors:  Jane Pritchard; Rui Han; Noah Horst; William W Cruikshank; Terry J Smith
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

10.  A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation.

Authors:  Elizabeth Clayton; Giuseppe Bardi; Sarah E Bell; David Chantry; C Peter Downes; Alexander Gray; Lisa A Humphries; David Rawlings; Helen Reynolds; Elena Vigorito; Martin Turner
Journal:  J Exp Med       Date:  2002-09-16       Impact factor: 14.307

View more
  38 in total

Review 1.  Potential role for bone marrow-derived fibrocytes in the orbital fibroblast heterogeneity associated with thyroid-associated ophthalmopathy.

Authors:  T J Smith
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

Review 2.  Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.

Authors:  Yao Wang; Terry J Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

Review 3.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

Review 4.  Immunopathogenesis of thyroid eye disease: emerging paradigms.

Authors:  Vibhavari M Naik; Milind N Naik; Robert A Goldberg; Terry J Smith; Raymond S Douglas
Journal:  Surv Ophthalmol       Date:  2010 May-Jun       Impact factor: 6.048

Review 5.  Delineating the autoimmune mechanisms in Graves' disease.

Authors:  Syed A Morshed; Rauf Latif; Terry F Davies
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

Review 6.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

7.  Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R(+) T cells.

Authors:  Allison N McCoy; Denise S Kim; Erin F Gillespie; Stephen J Atkins; Terry J Smith; Raymond S Douglas
Journal:  J Clin Endocrinol Metab       Date:  2014-03-26       Impact factor: 5.958

Review 8.  Thyroid eye disease: current and potential medical management.

Authors:  Jessica M Pouso-Diz; Jose M Abalo-Lojo; Francisco Gonzalez
Journal:  Int Ophthalmol       Date:  2020-01-09       Impact factor: 2.031

Review 9.  Current and Emerging Treatment Strategies for Graves' Orbitopathy.

Authors:  Natalia Genere; Marius N Stan
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

Review 10.  Potential Roles of CD34+ Fibrocytes Masquerading as Orbital Fibroblasts in Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith
Journal:  J Clin Endocrinol Metab       Date:  2019-02-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.